APELOA CDMO is the contract discovery, development, and manufacturing arm of Apeloa Pharmaceutical Co. Ltd., a subsidiary of the Hengdian Group, one of China’s largest private enterprises. As a CDMO, we are committed to delivering high-quality APIs, Intermediates, and Regulatory Starting Materials (RSMs). With over 30 years of experience, Apeloa has established itself as a reliable partner to the global pharmaceutical industry, offering services from R&D and scale-up to GMP commercial-scale production.

APELOA CDMO is a global leader in the development and manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Starting Materials at any stage. From early-stage development batches to fully commercialized GMP production, our highly skilled scientists and engineers provide customized solutions from our state-of-the-art facilities in China and the US. Our cost-effective CDMO services meet global regulatory and quality standards, driven by science and exceptional customer service, with a strong international presence.

Apeloa’s CDMO solutions and services include:
• API Process Development & Manufacturing
• HPAPI (OEB4 & OEB5)
• ADC (Payload + Linker)
• Synthetic Peptides (SPPS & LPPS)
• PROTAC
• LNP (CLs & ILs / PEG-Lipid)

• Medicinal Chemistry (Med. Chem)
• Full-Time Equivalent (FTE) services
• Analytical Development & Quality Control
• Global Regulatory Affairs CMC Filing
• Formulation Development & Manufacturing